



New A(H1N1) Strain Added to bioMérieux's Molecular Diagnostic Test NucliSENS EasyQ® Influenza A/B

Marcy l'Etoile, France – November 12, 2009 — A world leader in the field of *in vitro* diagnostics, bioMérieux has adapted its molecular NucliSENS EasyQ® Influenza A/B test to include the new A(H1N1) strain.

In line with its long-standing commitment to the fight against infectious diseases, bioMérieux has developed this new test to meet the needs of reference laboratories conducting pandemic surveillance. Based on bioMérieux's NASBA® Real-Time molecular technology, the test runs on the NucliSENS EasyQ® platform. It can detect the new H1N1 strain in less than 3 hours and is intended for Research Use Only. A CE marked version will be available in 2010.

“Since the first signs of the pandemic, bioMérieux has been contributing its expertise in infectious disease diagnostics and working with health authorities worldwide,” said Stéphane Bancel, bioMérieux's Chief Executive Officer. “Thanks to the agility and diligence of bioMérieux's R&D teams, we've been able to release this new version of our NucliSENS Influenza kit in less than 6 months.”

bioMérieux is playing an active role in the A(H1N1) pandemic and offers a wide range of products. The rapid test QuickVue® Influenza A+B is used for preliminary screening*. When results need to be confirmed, bioMérieux's range covers the complete cycle of molecular testing: extraction of nucleic acids with NucliSENS® easyMAG® and detection with EasyQ Influenza A/B. The company has also increased production and supply capacity of culture media used by pharmaceutical companies for vaccine quality control.

**Distributed by bioMérieux outside the United States, Japan and Scandinavian countries*

About bioMérieux

Advancing diagnostics to improve public health

A world leader in the field of *in vitro* diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2008, revenues reached €1.111 billion with 84% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Our products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).

Other information can be found at www.biomerieux.com

Contacts

Investor Relations

bioMérieux

Isabelle Tongio

Tel: + 33 4 78 87 22 37

investor.relations@eu.biomerieux.com

LT Value

Nancy Levain

Tel: + 33 1 44 50 39 30

nancy.levain@ltvalue.com

Media Relations

bioMérieux

Koren Wolman-Tardy

Tel: + 33 4 78 87 20 08

media@eu.biomerieux.com

Fleishman Hillard

Tim Baker

Tel: + 1 216-338-8086

Tim.Baker@fleishman.com

Image Sept

Laurence Heilbronn

Tel: + 33 1 53 70 74 64

lheilbronn@image7.fr

Tiphaine Hecketsweiler

Tel: + 33 1 53 70 74 59

thecketsweiler@image7.fr